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In 2010, we used our HIV clinic database located in 
the southern USA to develop a clinical proﬁ le of what 
HIV infection means at each decade of life, focusing 
speciﬁ cally on adults older than 50 years.1 Several of 
our ﬁ ndings were quite revealing. First, the prevalence 
of depression and anxiety is largely constant across 
the lifespan at roughly 40% and 20%, respectively. 
Second, the average number of prescribed drugs for 
individuals in their 50s was 12·48, which increased to 
14·82 for those aged 60 years or older. Third, although 
the average CD4 lymphocyte count ranged from 420 to 
479 in each decade of life, ANOVA analysis showed that 
older adults generally had signiﬁ cantly (p=0·018) 
lower viraemia than did adults in younger decades of 
life. Older adults were also more likely (p=0·001) to 
have an undetectable viral load (<50 RNA copies per 
ml) than were younger adults, with a prevalence of 
undetectable viral load of 65·4% for those in their 50s 
and 76·7% for those aged 60 years or older, compared 
with 36·2% for those in their 20s and 39·4% for those 
in their 30s. Finally, we noted that various distributions 
of comorbidities emerged across the lifespan (eg, con-
dyloma was more common in younger adults while 
alcohol misuse peaked in midlife [40–59 years]). How-
ever, the comorbidities that were most prevalent in 
our group of individuals aged 60 years or older were 
insomnia (17·8%), coronary artery disease (20·5%), 
hyper tension (67·1%), hypercholesterolaemia (65·8%), 
diabetes (28·8%), peripheral neuropathy (24·7%), 
hepatitis C (12·7%), and renal disease (23·3%).
Mikaela Smit and colleagues’ study2 far extends what 
we and others know about ageing with HIV infection 
and provides a statistical projection of what the clinical 
features of ageing with HIV will look like in 15 years. 
Theirs is the ﬁ rst study to provide such an advanced 
individual-based model to estimate clinical trends 
of ageing with HIV. Based on data from the national 
Dutch ATHENA cohort for more than 10 000 patients 
infected with HIV, they predicted that by 2030, 73% of 
individuals infected with HIV will be aged 50 years or 
older. By 2030, in this older group, 84% of individuals 
will have at least one additional comorbidity and 28% 
will have at least three, compared with 19% of HIV-
negative adults. The comorbidities underlying this 
increased prevalence will be malignancies (predicted 
for 17% of individuals), diabetes (predicted for 17% 
of individuals), and cardiovascular disease (predicted 
for 78% of individuals). This prediction supports 
the ﬁ ndings of several studies3,4 that suggest that 
such comorbidities will be of increasing importance, 
especially because these comorbidities might be partly 
caused by HIV-related inﬂ ammation and increased 
stress in this population.3,4 With treatments for such 
comorbidities, pharmacological burden will increase 
with respect to both the number of drugs needed and 
possible drug–drug interactions and contraindications 
with the ﬁ rst-line HIV regimens. Worryingly, Smit and 
colleagues2 predict that as many as 53% of individuals 
infected with HIV will have such drug–drug interactions 
in 2030. Further contributing to these interactions will 
be reductions in renal and hepatic functioning1 and 
decreases in patients’ adipose tissue, which will aﬀ ect 
pharmacokinetics and pharmacodynamics.3
Adults infected with HIV are expected to have close 
to normal lifespans5,6 and Smit and colleagues’ study 
provides a glimpse into the many challenges (eg, 
drug adherence, lifestyle modiﬁ cation, engagement 
in care) that will need to be addressed, especially in 
the resource-rich countries in which these ﬁ ndings 
are most applicable. One topic of particular interest is 
neurocognitive functioning.
At present, the prevalence of HIV-associated neuro-
cognitive disorders range from 52% to 59%.7,8 With 
increasing age, the prevalence and severity of neuro-
cognitive disorders might increase: Valcour and col-
leagues9 reported that older adults with HIV were three 
times more likely to develop HIV-associated dementia 
than were younger adults. Malignancies, diabetes, 
and cardiovascular disease already compromise 
brain reserve and neurocognitive function,10 and 
could exacerbate HIV-associated neuro cognitive dis-
order.5 Although older adults infected with HIV show 
superior drug adherence and compliance with medical 
appointments compared with younger adults,11 which 
might explain why many older adults are more likely to 
have suppressed viraemia,1 such advantages disappear 
when these older adults have neurocognitive loss.11 
In the long term, such neurocognitive losses can also 
reduce ability in driving, ﬁ nancial management, and 
other everyday tasks, which will disproportionately 
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increase need for formal and informal caregivers 
among aﬀ ected individuals.12,13
Smit and colleagues’ study2 contributes to the 
growing body of research on ageing with HIV 
and provides solid insights about what to expect 
for patients as they age. By extrapolation from 
these ﬁ ndings to other relevant areas, as we have 
done for neurocognitive functioning (eg, medical 
management, case management, retire ment issues), 
researchers, clinicians, and policy makers can plan to 
allocate resources accordingly to provide care to this 
growing geriatric population.
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Relief and worries about hepatitis C in sub-Saharan Africa
The hepatitis C pandemic is characterised by huge 
hetero geneity due to speciﬁ c national and local circum-
stances responsible for the spread of the virus in 
diﬀ erent populations. In sub-Saharan Africa, a com-
pre hensive survey1 analysing seroprevalence reported 
consistently high rates of anti-hepatitis C virus (HCV) 
marker in central Africa and estimated an overall 
prevalence of infection of 3% in the general population 
of that region. On the basis of recent developments in 
antiviral therapy, which imply that HCV quasieradication 
could be a realistic prospect, a reassessment of HCV 
epidemiology in sub-Saharan is necessary to identify 
priority measures to understand and subsequently 
reduce hepatitis C burden in that region. 
In a timely meta-analysis in The Lancet Infectious 
Diseases, V Bhargavi Rao and colleagues2 assessed 
anti-HCV records obtained between 2002 and 2014 
in 33 countries in sub-Saharan Africa, comprising 
1·2 million individuals from 287 cohorts. Among the 
salient ﬁ ndings of this study is the overall stability of 
HCV, with a present overall seroprevalence of 2·7% (vs 
3% in 2002), and the lasting heterogeneity between 
subregions, with central Africa still having higher rates of 
seropositive individuals (6·9% in 2015 vs 6·0% in 2002), 
south and east Africa improving their already better 
position (0·7% vs 1·6%), and west Africa undergoing 
somewhat of a deterioration of its previous situation 
(3·7% vs 2·4%). This ﬁ nding from west Africa is at odds 
with an analysis3 showing a decreased prevalence of HCV 
infection in west Africa between 1990 (4·0%) and 2005 
(2·8%). Improvements were also apparent in blood 
donors, with a general decrease in  anti-HCV carriage 
rate, conﬁ rming that transfusions have become safer 
in sub-Saharan Africa.4 To some extent, the situation 
of individuals in high-risk groups (eg, those with 
multiple transfusions, injecting drug users, health-care 
workers, prisoners) is also better in Rao and colleagues’ 
survey than it was in 2002. However, as for the general 
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